Clinical pharmacogenomics of carvedilol: the stereo-selective metabolism angle
- 1 September 2018
- journal article
- editorial
- Published by Taylor & Francis Ltd in Pharmacogenomics
- Vol. 19 (14), 1089-1093
- https://doi.org/10.2217/pgs-2018-0115
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and MetoprololCurrent Drug Metabolism, 2015
- Polymorphic Variants of Adrenoceptors: Pharmacology, Physiology, and Role in DiseasePharmacological Reviews, 2014
- Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failureJournal of Clinical Pharmacy & Therapeutics, 2014
- Mutual Inhibition between Carvedilol Enantiomers during Racemate Glucuronidation Mediated by Human Liver and Intestinal MicrosomesBiological & Pharmaceutical Bulletin, 2012
- Stereoselective Glucuronidation of Carvedilol in Human Liver and Intestinal MicrosomesPharmacology, 2012
- Pharmacokinetic Profile of Controlled-Release Carvedilol in Patients with Left Ventricular Dysfunction Associated with Chronic Heart Failure or After Myocardial InfarctionThe American Journal of Cardiology, 2006
- Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference?European Journal of Clinical Pharmacology, 2006
- Characterization of β‐adrenoceptor antagonists as substrates and inhibitors of the drug transporter P‐glycoprotein1Fundamental & Clinical Pharmacology, 2006
- INVOLVEMENT OF HUMAN HEPATIC UGT1A1, UGT2B4, AND UGT2B7 IN THE GLUCURONIDATION OF CARVEDILOLDrug Metabolism and Disposition, 2004
- Cardiac adrenergic receptor effects of carvedilolEuropean Heart Journal, 1996